These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 26333383)

  • 41. Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).
    Cocco E; Javier Carmona F; Razavi P; Won HH; Cai Y; Rossi V; Chan C; Cownie J; Soong J; Toska E; Shifman SG; Sarotto I; Savas P; Wick MJ; Papadopoulos KP; Moriarty A; Cutler RE; Avogadri-Connors F; Lalani AS; Bryce RP; Chandarlapaty S; Hyman DM; Solit DB; Boni V; Loi S; Baselga J; Berger MF; Montemurro F; Scaltriti M
    Sci Signal; 2018 Oct; 11(551):. PubMed ID: 30301790
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
    Menendez JA; Vellon L; Lupu R
    Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Saura C; Hlauschek D; Oliveira M; Zardavas D; Jallitsch-Halper A; de la Peña L; Nuciforo P; Ballestrero A; Dubsky P; Lombard JM; Vuylsteke P; Castaneda CA; Colleoni M; Santos Borges G; Ciruelos E; Fornier M; Boer K; Bardia A; Wilson TR; Stout TJ; Hsu JY; Shi Y; Piccart M; Gnant M; Baselga J; de Azambuja E
    Lancet Oncol; 2019 Sep; 20(9):1226-1238. PubMed ID: 31402321
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeted therapy in the treatment of uterine serous carcinoma.
    Schwab CL; Santin AD
    Pharmacogenomics; 2015 Jan; 16(2):97-9. PubMed ID: 25616096
    [No Abstract]   [Full Text] [Related]  

  • 45. Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models.
    Moore HM; Savage HM; O'Brien C; Zhou W; Sokol ES; Goldberg ME; Metcalfe C; Friedman LS; Lackner MR; Wilson TR
    Mol Cancer Ther; 2020 Jan; 19(1):292-303. PubMed ID: 31534012
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.
    Vora SR; Juric D; Kim N; Mino-Kenudson M; Huynh T; Costa C; Lockerman EL; Pollack SF; Liu M; Li X; Lehar J; Wiesmann M; Wartmann M; Chen Y; Cao ZA; Pinzon-Ortiz M; Kim S; Schlegel R; Huang A; Engelman JA
    Cancer Cell; 2014 Jul; 26(1):136-49. PubMed ID: 25002028
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancer.
    Fiascarelli A; Merlino G; Capano S; Talucci S; Bisignano D; Bressan A; Bellarosa D; Carrisi C; Paoli A; Bigioni M; Tunici P; Irrissuto C; Salerno M; Arribas J; de Stanchina E; Scaltriti M; Binaschi M
    Breast Cancer Res Treat; 2023 May; 199(1):13-23. PubMed ID: 36913051
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Uterine serous carcinoma: Molecular features, clinical management, and new and future therapies.
    Lee EK; Fader AN; Santin AD; Liu JF
    Gynecol Oncol; 2021 Jan; 160(1):322-332. PubMed ID: 33160694
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.
    Chia SKL; Martin M; Holmes FA; Ejlertsen B; Delaloge S; Moy B; Iwata H; von Minckwitz G; Mansi J; Barrios CH; Gnant M; Tomašević Z; Denduluri N; Šeparović R; Kim SB; Jakobsen EH; Harvey V; Robert N; Smith J; Harker G; Zhang B; Eli LD; Ye Y; Lalani AS; Buyse M; Chan A
    Breast Cancer Res; 2019 Mar; 21(1):39. PubMed ID: 30867034
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab.
    Todeschini P; Cocco E; Bellone S; Varughese J; Lin K; Carrara L; Guzzo F; Buza N; Hui P; Silasi DA; Ratner E; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Br J Cancer; 2011 Oct; 105(8):1176-82. PubMed ID: 21915118
    [TBL] [Abstract][Full Text] [Related]  

  • 51. HER2 in uterine serous carcinoma: Current state and clinical perspectives.
    Navarro Sanchez JM; Finkelman BS; Turner BM; Katerji H; Wang X; Varghese S; Wang T; Peng Y; Hicks DG; Zhang H
    Am J Clin Pathol; 2023 Oct; 160(4):341-351. PubMed ID: 37267036
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity.
    Hanker AB; Brown BP; Meiler J; Marín A; Jayanthan HS; Ye D; Lin CC; Akamatsu H; Lee KM; Chatterjee S; Sudhan DR; Servetto A; Brewer MR; Koch JP; Sheehan JH; He J; Lalani AS; Arteaga CL
    Cancer Cell; 2021 Aug; 39(8):1099-1114.e8. PubMed ID: 34171264
    [TBL] [Abstract][Full Text] [Related]  

  • 53. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
    Wang Q; Liu P; Spangle JM; Von T; Roberts TM; Lin NU; Krop IE; Winer EP; Zhao JJ
    Oncogene; 2016 Jul; 35(27):3607-12. PubMed ID: 26500061
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer.
    Korkola JE; Collisson EA; Heiser M; Oates C; Bayani N; Itani S; Esch A; Thompson W; Griffith OL; Wang NJ; Kuo WL; Cooper B; Billig J; Ziyad S; Hung JL; Jakkula L; Feiler H; Lu Y; Mills GB; Spellman PT; Tomlin C; Mukherjee S; Gray JW
    PLoS One; 2015; 10(7):e0133219. PubMed ID: 26181325
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216.
    Walls M; Baxi SM; Mehta PP; Liu KK; Zhu J; Estrella H; Li C; Zientek M; Zong Q; Smeal T; Yin MJ
    Clin Cancer Res; 2014 Feb; 20(3):631-43. PubMed ID: 24240111
    [TBL] [Abstract][Full Text] [Related]  

  • 56. T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2.
    Nicoletti R; Lopez S; Bellone S; Cocco E; Schwab CL; Black JD; Centritto F; Zhu L; Bonazzoli E; Buza N; Hui P; Mezzanzanica D; Canevari S; Schwartz PE; Rutherford TJ; Santin AD
    Clin Exp Metastasis; 2015 Jan; 32(1):29-38. PubMed ID: 25398397
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combination effect of lapatinib with foretinib in HER2 and MET co-activated experimental esophageal adenocarcinoma.
    Hassan MS; Williams F; Awasthi N; Schwarz MA; Schwarz RE; Li J; von Holzen U
    Sci Rep; 2019 Nov; 9(1):17608. PubMed ID: 31772236
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
    Leto SM; Sassi F; Catalano I; Torri V; Migliardi G; Zanella ER; Throsby M; Bertotti A; Trusolino L
    Clin Cancer Res; 2015 Dec; 21(24):5519-31. PubMed ID: 26296355
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhibition of gamma-secretase activity impedes uterine serous carcinoma growth in a human xenograft model.
    Groeneweg JW; Hall TR; Zhang L; Kim M; Byron VF; Tambouret R; Sathayanrayanan S; Foster R; Rueda BR; Growdon WB
    Gynecol Oncol; 2014 Jun; 133(3):607-15. PubMed ID: 24667249
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer.
    Nam HJ; Ching KA; Kan J; Kim HP; Han SW; Im SA; Kim TY; Christensen JG; Oh DY; Bang YJ
    Mol Cancer Ther; 2012 Feb; 11(2):439-51. PubMed ID: 22135232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.